104 related articles for article (PubMed ID: 8158774)
1. Testicular androgens in prostate cancer patients treated with a luteinizing hormone releasing hormone agonist.
Hudson PB; Hakky SI; Lombardo ME
J Urol; 1994 May; 151(5):1281-2. PubMed ID: 8158774
[TBL] [Abstract][Full Text] [Related]
2. Luteinizing hormone (LH)-releasing hormone agonist reduces serum adrenal androgen levels in prostate cancer patients: implications for the effect of LH on the adrenal glands.
Nishii M; Nomura M; Sekine Y; Koike H; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
J Androl; 2012; 33(6):1233-8. PubMed ID: 22492843
[TBL] [Abstract][Full Text] [Related]
3. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
4. Effects of the duration of therapy with the LHRH agonist D-ser (BUT)6 Azgly10-LHRH (ICI 118-630) on the steroid hormone content and the morphology of human testicular tissue in the treatment of patients with advanced prostate cancer.
Kuber W; Viehberger G; Zeillinger R; Spona J
Urol Res; 1991; 19(1):19-24. PubMed ID: 1827557
[TBL] [Abstract][Full Text] [Related]
5. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia.
Eri LM; Haug E; Tveter KJ
Scand J Clin Lab Invest; 1996 Jul; 56(4):319-25. PubMed ID: 8837238
[TBL] [Abstract][Full Text] [Related]
6. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
Oefelein MG; Cornum R
J Urol; 2000 Sep; 164(3 Pt 1):726-9. PubMed ID: 10953134
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
Santen RJ; Warner B
Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
[TBL] [Abstract][Full Text] [Related]
8. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
9. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
10. Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer.
Bonzani RA; Stricker HJ; Peabody JO; Menon M
J Urol; 1998 Dec; 160(6 Pt 2):2446-9. PubMed ID: 9817400
[TBL] [Abstract][Full Text] [Related]
11. Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations.
Reis LO; Denardi F; Faria EF; Silva ED
Am J Mens Health; 2015 Sep; 9(5):430-4. PubMed ID: 25294865
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
13. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
[TBL] [Abstract][Full Text] [Related]
14. Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer.
Fankhauser M; Tan Y; Macintyre G; Haviv I; Hong MK; Nguyen A; Pedersen JS; Costello AJ; Hovens CM; Corcoran NM
Clin Cancer Res; 2014 Nov; 20(21):5547-57. PubMed ID: 24771644
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.
Lawrentschuk N; Fernandes K; Bell D; Barkin J; Fleshner N
J Urol; 2011 Mar; 185(3):848-54. PubMed ID: 21239017
[TBL] [Abstract][Full Text] [Related]
16. Gonadal in vitro androstenedione metabolism and changes in some plasma and gonadal steroid hormones during sex inversion of the protandrous sea bass, Lates calcarifer.
Guiguen Y; Jalabert B; Benett A; Fostier A
Gen Comp Endocrinol; 1995 Oct; 100(1):106-18. PubMed ID: 8575651
[TBL] [Abstract][Full Text] [Related]
17. Elucidation of the mechanism of suppressed steroidogenesis during androgen deprivation therapy of prostate cancer patients using a mouse model.
Taniguchi H; Katano T; Nishida K; Kinoshita H; Matsuda T; Ito S
Andrology; 2016 Sep; 4(5):964-71. PubMed ID: 27230983
[TBL] [Abstract][Full Text] [Related]
18. In vitro studies on the inhibition of testosterone synthesis in the human testis by atamestane.
Lombardo ME; Hakky SI; Hudson PB
J Steroid Biochem Mol Biol; 1993 Mar; 44(3):287-90. PubMed ID: 8384873
[TBL] [Abstract][Full Text] [Related]
19. Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.
van der Sluis TM; van Moorselaar RJ; Meuleman EJ; ter Haar RW; Bui HN; Heijboer AC; Vis AN
Urology; 2013 May; 81(5):1005-9. PubMed ID: 23465153
[TBL] [Abstract][Full Text] [Related]
20. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
van der Sluis TM; Bui HN; Meuleman EJ; Heijboer AC; Hartman JF; van Adrichem N; Boevé E; de Ronde W; van Moorselaar RJ; Vis AN
J Urol; 2012 May; 187(5):1601-6. PubMed ID: 22425112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
